Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
These 2 No-Brainer Growth Stocks Are Breaking New Ground
07:15am, Thursday, 16'th May 2024
Eli Lilly and Regeneron are developing competing hearing-loss gene therapies. These drugmakers have solid businesses thanks to their innovative qualities.
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
Calls of the Day: Roblox, Regeneron, Costco and Edison
01:34pm, Tuesday, 14'th May 2024
The Investment Committee discuss the latest Calls of the Day
Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
12:42pm, Tuesday, 14'th May 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 14, 2024 9:00 AM ET Company Participants Ryan Crowe - Senior Vice President of Investor Relations & St
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammat
Will the Biotech Sector Shift From Lagger to Leader?
07:24am, Friday, 10'th May 2024
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector ha
Regeneron's experimental gene therapy improves hearing in one patient
06:11am, Wednesday, 08'th May 2024
Regeneron Pharmaceuticals said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage study.
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness
Regeneron Announces Investor Conference Presentations
04:05pm, Monday, 06'th May 2024
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
12:00pm, Saturday, 04'th May 2024
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untr
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
06:15am, Friday, 03'rd May 2024
Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command ex
Regeneron's Q1 Results Came Up a Bit Short
07:07pm, Thursday, 02'nd May 2024
The biotech missed analysts' expectations on both EPS and revenue. Dupixent and Libtayo delivered substantial sales growth.
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
11:06am, Thursday, 02'nd May 2024
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
10:36am, Thursday, 02'nd May 2024
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Stree
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
07:15am, Thursday, 02'nd May 2024
CRISPR Therapeutics, Regeneron, and Sanofi all deserve a close look now. These three biotechs have important growth drivers on the market.
